Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists

Published:2021-12-17 Issue:2 Volume:11 Page:530-538
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Mileham Kathryn F.¹,Schenkel Caroline²^ORCID,Bruinooge Suanna S.²,Freeman‐Daily Janet³,Basu Roy Upal⁴,Moore Amy⁴,Smith Robert A.⁵^ORCID,Garrett‐Mayer Elizabeth²^ORCID,Rosenthal Lauren⁵,Garon Edward B.⁶,Johnson Bruce E.⁷,Osarogiagbon Raymond U.⁸,Jalal Shadia⁹,Virani Shamsuddin¹⁰,Weber Redman Mary¹¹,Silvestri Gerard A.⁵

Affiliation:

1. Levine Cancer Institute Atrium Health Charlotte North Carolina USA

2. American Society of Clinical Oncology Alexandria Virginia USA

3. The ROS1ders Mountain View California USA

4. LUNGevity Foundation Chicago Illinois USA

5. American Cancer Society National Lung Cancer Roundtable Atlanta Georgia USA

6. University of California Los Angeles David Geffen School of Medicine Los Angeles California USA

7. Dana‐Farber Cancer Institute Boston Massachusetts USA

8. Baptist Cancer Center Memphis Tennessee USA

9. Indiana University Indianapolis Indiana USA

10. Aurora Health Care Burlington Wisconsin USA

11. Fred Hutchinson Cancer Research Center Seattle Washington USA

Funder

American Society of Clinical Oncology

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4459

Reference20 articles.

1. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

3. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

4. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

5. Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancer;Journal of Managed Care & Specialty Pharmacy;2024-09-11

2. Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective;Neuropsychopharmacology;2024-08-21

3. Half of oncologists fail to use ordered NGS results to guide their first-line treatment decision in advanced NSCLC: A retrospective study in a community-based integrated healthcare system;Heliyon;2024-08

4. Factors associated with next generation sequencing-based testing among patients with advanced/metastatic non-squamous non-small cell lung cancer: A study using machine learning methods (Preprint);2024-07-16

5. NTRK gene fusion testing and management in lung cancer;Cancer Treatment Reviews;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3